LSITIRPR* – SIL Dupilumab signature peptide quantifier

LSITIRPR Stable Isotope Labeled Infliximab (DPL) peptide serves as an internal standard to confirm DPL’s primary sequence by mass spectrometry. This allows expected sequences to be confirmed and terminal amino acid homogeneity to be assessed.

SB-PEPTIDE’s Dupilumab SIL signature peptide quantifier is designed and optimized to provide the best mass spectrometry performance during your Mass Spec assay. For a better detection and quantification,you can use Dupilumab SIL peptide qualifier,that will induce a complementary signal,with a lower signal-to-noise ratio,for DPL presence confirmation.

Technical specification

Price